Research programme: radiopharmaceutical diagnostics and therapeutics - Fuzionaire Theranostics/McMaster University
Latest Information Update: 02 Aug 2023
At a glance
- Originator Fuzionaire Diagnostics; McMaster University
- Developer Fuzionaire Theranostics; McMaster University
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 31 Jul 2023 Fuzionaire Diagnostics is now called Fuzionaire Theranostics
- 06 Jul 2022 Early research in Cancer in Canada (Parenteral)
- 06 Jul 2022 Early research in Cancer in USA (Parenteral)